Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Vancouver-based Zymeworks Inc. (NASDAQ: ZYME; TSX: ZYME) cleared its most pivotal regulatory milestone to date on October 22, 2026, as the U.S. Food and Drug Administration granted full approval to zanidatamab (brand name: Ziihera) for adult patients with previously treated, unresectable or metastatic HER2-amplified biliary tract cancer (BTC). The approval, based on the Phase 2b HERIZON-BTC-01 trial, confirms an overall response rate of 41.3% with a median duration of response of 12.9 months — data that exceeded the agency’s benchmark for accelerated pathways and supported a full, traditional approval.

The Indication and Patient Population

Biliary tract cancer — encompassing cholangiocarcinoma and gallbladder cancer — is a rare but aggressive malignancy. Approximately 12,000 new cases are diagnosed annually in the United States, with an estimated 15–20% classified as HER2-amplified, yielding a targetable population of roughly 1,800–2,400 patients per year in the U.S. alone. These patients have historically faced a median overall survival of under 8 months following first-line chemotherapy failure. Zanidatamab is a bispecific antibody targeting two distinct HER2 epitopes simultaneously, a mechanism that differentiates it from legacy trastuzumab-based regimens and has demonstrated durable responses in a population with almost no approved second-line options until now.

Commercial Opportunity and Competitive Landscape

Wall Street consensus pegs the global BTC market at approximately USD $1.4 billion by 2029, with zanidatamab peak sales estimates clustering in the USD $600–$850 million range across all licensed territories — equivalent to roughly CAD $843 million–$1.19 billion at today’s USD/CAD rate of 1.4046. Zymeworks’ global commercialization partner, Jazz Pharmaceuticals, holds ex-China rights and will bear the bulk of the U.S. sales infrastructure cost, meaning Zymeworks is entitled to tiered royalties and milestone payments rather than carrying a full commercial burn. The primary competitive threat comes from AstraZeneca’s trastuzumab deruxtecan (Enhertu), which is pursuing a BTC label expansion; however, zanidatamab’s distinct bispecific mechanism and cleaner safety profile — notably a lower rate of interstitial lung disease — are viewed by oncologists as meaningful differentiators. A BeiGene partnership covers Greater China rights, providing additional geographic revenue diversification.

Health Canada Pathway and Canadian Investor Angle

Zymeworks confirmed in an accompanying press release that a Health Canada New Drug Submission (NDS) is on track for filing within 90 days, leveraging the FDA package under Canada’s Project Orbis framework, which enables concurrent review with international regulators. Canadian approval, if granted, would open access to an estimated 400–600 eligible Canadian patients annually, with reimbursement negotiations through CADTH (Canadian Drug Review) expected to follow an 18–24 month timeline. The TSX-listed shares give Canadian retail investors direct exposure without currency conversion friction.

Stock Reaction and Long-Term Thesis

ZYME shares surged 28.4% in pre-market trading on the Nasdaq ahead of the October 22 open, recovering substantially from a 14-month consolidation range. The XBI biotech ETF was down 0.30% to $152.78 on the same session, underscoring that today’s move is company-specific rather than a sector tailwind. For long-term investors, the approval de-risks the most binary element of the thesis: zanidatamab’s regulatory credibility now supports its pipeline applications in gastroesophageal adenocarcinoma (GEA) and breast cancer, both of which are materially larger addressable markets. The key remaining catalyst is readout of the HERIZON-GEA-01 Phase 3 trial, expected in Q2 2027, which targets a patient population roughly five times the size of the BTC cohort. Investors should monitor Jazz’s commercial execution in Q1 2027 and the Health Canada review timeline as the next concrete milestones.